Major cancer trial tests new hope for patients Who've run out of options
NCT ID NCT02628067
Summary
This study tested pembrolizumab, an immunotherapy drug, in people with advanced solid tumors who had already tried standard treatments that stopped working. Researchers enrolled 1,609 participants with various cancers including anal, cervical, lung, and thyroid cancers to see how well the drug worked and to identify biological markers that might predict who would benefit most. The goal was to control cancer growth and extend survival for patients with limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.